Prescription Medicines
Valdipine Tab. 5/80mg
- Product Category
- Complex hypertension treatment
- Active Ingredients
- Valsartan, amlodipine besylate
- Appearance
- Dark yellow round film-coated tablets
- Reimbursement Code
- 648103300
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Amlodipine besylate (USP) ---------- 6.94mg (5mg as amlodipine)
Valsartan (in-house specification) ---------- 80mg
- Additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03B620011), colloidal silicon oxide, crospovidone
2. Efficacy/Effectiveness
Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy
3. Usage/Dosage
The recommended dosage of this medicine is 1 tablet once a day, taken with water regardless of meals. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (amlodipine or valsartan) before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient as follows, you can consider switching to this medicine right away.
・ 5/80 milligram: Administered to patients whose blood pressure is not properly controlled by monotherapy with 5 milligrams of amlodipine or 80 milligrams of valsartan.
・ 5/160 milligram: Administered to patients whose blood pressure is not properly controlled with monotherapy with 5 milligrams of amlodipine or 160 milligrams of valsartan.
・ 10/160 milligram: Administer to patients whose blood pressure is not properly controlled with 10 milligrams of amlodipine or 160 milligrams of valsartan as monotherapy or 5/160 milligrams.
If a patient is taking valsartan and amlodipine in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
- Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance of 10 mL/min or more), but this drug should not be administered to patients with severe renal impairment (creatinine clearance of less than 10 mL/min) or dialysis patients. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended.
- Patients with hepatic impairment: For patients with mild and moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. Severe liver failure, biliary cirrhosis, biliary obstruction, bile secretion arrest
Do not administer this medicine to these patients.
- Elderly people over 65 years of age: Caution should be exercised when increasing the dose.
- Children: Administration of this drug is not recommended for pediatric patients under the age of 18 as the safety and efficacy have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, they can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant and lactating women)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe renal impairment (creatinine clearance less than 10 mL/min) (no experience with use)
4) Patients with severe liver impairment, biliary cirrhosis, biliary obstruction, or bile secretion arrest
5) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
6) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
7) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
8) Patients with severe aortic stenosis
9) Shock patients
3. Administer with caution to the following patients:
1) Patients with sodium and/or fluid deficiency
In placebo-controlled clinical trials, excessive hypotension was observed in 0.4% of patients with uncomplicated hypertension receiving this drug. In patients with an activated renin-angiotensin system who are taking angiotensin receptor antagonists (ARB antagonists) (e.g., volume and/or sodium depleted patients taking high doses of diuretics), symptomatic hypotension may occur. It is recommended that these conditions be corrected prior to administration of this drug or that close medical observation be observed upon initiation of treatment.
If low blood pressure occurs when taking this medicine, have the patient lie down and, if necessary, inject saline solution intravenously. Treatment can be continued after blood pressure stabilizes.
2) Patients with hyperkalemia
Caution should be exercised when coadministering this drug with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
3) Patients with renal artery stenosis
This drug may increase blood urea and serum creatinine in patients with bilateral or unilateral renal artery stenosis caused by valsartan or in patients with short stature and stenosis, so monitoring is recommended for safety.
4) Kidney transplant patient
There are no data to demonstrate the safe use of this drug in patients who have recently undergone a kidney transplant.
5) Angioedema
Angioedema (including swelling of the larynx and glottis) causing airway obstruction and/or swelling of the face, lips, and tongue has been reported in patients receiving valsartan. Some of these patients had experienced angioedema caused by other medications, such as ACE inhibitors. If angioedema occurs during administration of this drug, administration should be discontinued immediately and should not be re-administered.
6) Patients after heart failure or myocardial infarction
In general, caution is advised when using calcium channel antagonists such as amlodipine in patients with severe congestive heart failure (NYHA class III or IV). In a placebo-controlled trial (PRIASE-2) in patients with NYHA stage III or IV heart failure of nonischemic origin, amlodipine was reported to be associated with an increase in pulmonary edema despite clearly reducing exacerbations of heart failure compared to placebo.
In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., severe heart failure), administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
7) Patients with acute myocardial infarction
In patients who started taking or increased the dose of calcium channel blockers (e.g., amlodipine) (especially patients with severe obstructive coronary artery disease), increases in the frequency, duration, or severity of angina or acute myocardial infarction were rarely reported.
8) Patients with aortic and mitral valve stenosis and obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is required when administering amlodipine to patients with aortic or mitral atresia or obstructive hypertrophic cardiomyopathy.
9) Dual blockade of renin-angiotensin-aldosterone system (RAAS):
Concomitant use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, including valsartan, is not recommended.
10) Patients with mild to moderate hepatic impairment (In patients with mild to moderate hepatic impairment, it is recommended that the daily dose of valsartan among the ingredients of this drug do not exceed 80 mg.)
4. Adverse reactions
1) The safety of this drug was evaluated in 5 controlled clinical trials in which 5,175 patients participated, of which 2,613 received amlodipine and valsartan in combination.
Adverse reactions were classified according to frequency of occurrence into very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1,000, <1/100), rare (≥ 1/10,000, <1/1,000), and very rare (<1/10,000), including independent reports. In the same frequency group, adverse reactions were organized in decreasing order of seriousness.
<Table 1> Adverse reactions that occurred (please refer to the attached document for details)
2) Additional information on combination use
In a double-blind, drug- or placebo-controlled clinical trial, the incidence of peripheral edema was found to be statistically lower in the combined amlodipine group (5.8%) compared to the amlodipine group administered alone (9%).
3) Additional information about each active ingredient
Although not observed in clinical trials and post-marketing experience with this drug, adverse reactions previously reported for each ingredient may occur.
① Valsartan
<Table 2> Adverse drug reactions that occurred when valsartan was administered alone
(Please refer to the attached document for further details)
Regardless of the causal relationship with the drug, the following symptoms were reported during clinical trials: insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
② Amlodipine
Regardless of the causal relationship with the drug, adverse reactions reported in amlodipine clinical trials are listed in <Table 3>.
<Table 3> Adverse reactions that occurred when amlodipine was administered alone
(Please refer to the attached document for further details)
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization. Leukopenia, thrombocytopenia, confusion, exfoliative dermatitis, Stevenson-Johnson syndrome, photosensitivity reaction, and toxic epidermal necrolysis have been reported (frequency unknown).
4) Domestic post-marketing survey results
(1) As a result of a use result survey conducted on 859 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 5.12% (44 people, 56 cases) regardless of causal relationship.
The incidence of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 1.75% (15 people, 19 cases), headache 0.47% (4 people, 4 cases), dizziness 0.35% (3 people, 3 cases), itching 0.35% (3 people, 3 cases), peripheral edema 0.23% (2 people, 2 cases), and hypotension. 0.23% (2 people, 2 cases), 1 case each of edema, chest pain, pain, cough, and enuresis.
Regardless of the causal relationship with this drug, no serious adverse events have been reported. A total of 9 cases were reported as unexpected adverse events, including 0.23% chest discomfort (2 people, 2 cases), pain, abdominal discomfort, reflux esophagitis, neck pain, hypercholesterolemia, hypoglycemia, and enuresis. A total of 2 unexpected drug adverse reactions occurred, 1 case of pain and 1 case of enuresis.
(2) As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, the following are newly identified adverse events that were statistically significantly more reported in this drug compared to the adverse events reported in all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
∙ Systemic abnormalities: chest pain, weight gain
∙ Musculoskeletal system: joint pain, skeletal pain, rhabdomyolysis
∙ Oral: Gum hyperplasia
∙ Gastrointestinal system: Gastritis
∙ Mental disorder: nervousness
∙ Nervous system: decreased sensation
∙ Skin and subcutaneous tissue abnormalities: Stevens-Johnson syndrome
5. General precautions
1) Be careful when driving and operating machines
Clinical trials have not been conducted on the effects on driving and using machinery. It should be taken into account that dizziness and fatigue may occur intermittently when driving or using machinery. As with other antihypertensive drugs, take special care when driving or operating machinery.
2) Valsartan
(1) Administration of this drug may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration. In such cases, stop administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
➀ Patients undergoing hemodialysis
② Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
③ Patients undergoing strict salt restriction
(2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of taking this drug. This depletion of sodium and body fluids before administration of this drug should be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
(3) Patients with renal artery stenosis: Short-term administration of this drug to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow and a decrease in glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
(4) It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment does not exceed 80 mg. This drug is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when this drug is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
(5) Patients receiving this drug after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of hypotension. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with this drug. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of this drug and/or diuretic should be considered.
(6) In patients with hyperkalemia, administration should be avoided except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
(7) There is no experience of use in patients who recently underwent kidney transplantation.
(8) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
3) Amlodipine
(1) Administration to heart failure patients: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in NYHA class III and IV heart failure patients without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared to placebo.
(2) Administration to patients with liver dysfunction: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
(3) Since the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration, so when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
(4) Since the effect appears slowly, it cannot be expected to be effective in unstable angina pectoris that requires emergency treatment.
6. Interaction
1) Valsartan
① Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
② Potassium: Caution should be exercised when using potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
③ Non-steroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect may be reduced when angiotensin II receptor antagonists are administered simultaneously with NSAIDs (e.g., aspirin as anti-inflammatory therapy, COX-2 inhibitors). In particular, the risk of kidney function deterioration may increase in elderly patients, patients with insufficient body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
④ Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
⑤ When valsartan was administered alone, no clinically significant drug interactions were observed with the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glibenclamide.
2) Amlodipine
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. The maximum daily dose of simvastatin in patients receiving amlodipine is 20 mg.
② CYP3A4 inhibitor: When the elderly administered a combination of 5 mg of amlodipine and 180 mg of diltiazem per day, the systemic exposure of amlodipine increased by 57%. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase the blood concentration of amlodipine more than diltiazem, so amlodipine should be administered with caution when co-administered with CYP3A4 inhibitors.
③ CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
④ Others: When amlodipine is administered alone, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin converting enzyme inhibitors, long-acting nitrate preparations, nitroglycerin sublingual tablets, digoxin, warfarin, atorovastatin, sildenafil, aluminum/magnesium (antacid), cimetidine, non-steroidal drugs. It was safe when used in combination with anti-inflammatory drugs, antibiotics, oral hypoglycemic agents, ethanol (alcohol), and cyclosporine.
⑤ Grapefruit juice: A single oral administration of 240 mL of grapefruit juice and 10 mg of amlodipine to 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodine.
⑥ Tacrolimus: When administered in combination with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II antagonists, a risk to the fetus cannot be excluded. Damage to the developing fetus and death have been reported in pregnant women taking angiotensin-converting enzyme inhibitors (a special group of drugs that act on the renin-angiotensin-allosterone system (RAAS)) during the second and third trimesters. And the use of ACE inhibitors in the first trimester is associated with a potential risk of fetal malformations. Spontaneous abortion, oligohydramnios, and renal dysfunction in newborns have been reported in pregnant women who accidentally took valsartan. Like other medications that act directly on the RAAS, this medication should not be used during pregnancy or if you plan to become pregnant. When prescribing drugs that act on RAAS to women who may become pregnant, doctors should explain the potential risks of these drugs during pregnancy. If pregnancy is confirmed during treatment with this drug, this drug should be discontinued as soon as possible.
2) It is not known whether valsartan and/or amlodipine are secreted into milk in humans, but in rats, valsartan was secreted into milk. Therefore, it is not recommended for breastfeeding women to use this medicine.
3) There have been no clinical studies on reproductive function of this drug or each single agent. There is no non-clinical data on reproductive function for this drug, but non-clinical tests conducted with each component of valsartan and amlodipine did not show an effect on reproductive function.
8. Administration to children
This drug is not recommended for use in patients under the age of 18 as there is insufficient data on its safety and effectiveness.
9. Administration to elderly people
Both components of this drug were well tolerated when similar doses were used in adults and the elderly, so normal doses are recommended.
10. Effect on clinical test values
1) Among patients with hypertension who received valsartan/amlodipine, there were very few patients whose test values clearly changed from baseline. The amlodipine/valsartan combination group (5.5%) and the valsartan alone group (5.5%) showed higher blood urea nitrogen (BUN) than the placebo group (4.5%).
2) An increase in liver function test values has occasionally been reported when administering valsartan, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
11. Treatment in case of overdose
I have no experience of overdosing on this drug. When overdosing on valsartan, the main symptoms may be low blood pressure accompanied by dizziness. Overdosage of amlodipine may cause reflex tachycardia by excessively dilating peripheral blood vessels. There have been reported cases of prolonged systemic hypotension leading to shock and even death.
If clinically significant hypotension occurs due to overdosage of this drug, active cardiovascular therapy should be implemented, including frequent monitoring of cardiac and respiratory function, keeping extremities elevated, and careful monitoring of circulating fluid volume and urine output. If the use of vasoconstrictors is not contraindicated, they may help restore vascular tone and blood pressure. Intravenous calcium gluconate may help reverse calcium channel blockage. Neither valsartan nor amlodipine are removed by hemodialysis. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors. Immediately after an overdose of this drug, inducing vomiting or gastric lavage may be considered. When medicinal charcoal was administered immediately to 2 hours after taking amlodipine in healthy volunteers, it significantly reduced amlodipine absorption.
12. Pharmaceutical equivalence test information
A. The test drug Valdipine Tablet 10/160 mg [KyungDong Pharm Co., Ltd.] and the reference drug Expo-designated 10/160 mg) [Novartis Korea Co., Ltd.] were orally administered as a single dose to healthy adults in a 2 In this case, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
(Please refer to the attached document for further details)
13. Others
In the embryo-fetal toxicity study in rats and in the 13-week animal study in rats and marmosets, there were no toxicological findings that would be considered significant in humans.
As a result of oral administration in rats for 13 weeks, glandular inflammation was observed in male rats administered more than 3/48 mg/kg/day of amlodipine/valsartan, but not in female rats. In marmosets, this result was not observed at any dose, but colitis was observed at high doses (no effects were observed below 5/80 mg/kg/day). In clinical trials, the frequency of gastrointestinal adverse reactions observed when administering this drug was similar to the frequency of adverse reactions observed when administered alone.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets (7 tablets/Alu-AluX4), 30 tablets/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Amlodipine besylate (USP) ---------- 6.94mg (5mg as amlodipine)
Valsartan (in-house specification) ---------- 80mg
- Additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03B620011), colloidal silicon oxide, crospovidone
2. Efficacy/Effectiveness
Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy
3. Usage/Dosage
The recommended dosage of this medicine is 1 tablet once a day, taken with water regardless of meals. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (amlodipine or valsartan) before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient as follows, you can consider switching to this medicine right away.
・ 5/80 milligram: Administered to patients whose blood pressure is not properly controlled by monotherapy with 5 milligrams of amlodipine or 80 milligrams of valsartan.
・ 5/160 milligram: Administered to patients whose blood pressure is not properly controlled with monotherapy with 5 milligrams of amlodipine or 160 milligrams of valsartan.
・ 10/160 milligram: Administer to patients whose blood pressure is not properly controlled with 10 milligrams of amlodipine or 160 milligrams of valsartan as monotherapy or 5/160 milligrams.
If a patient is taking valsartan and amlodipine in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
- Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance of 10 mL/min or more), but this drug should not be administered to patients with severe renal impairment (creatinine clearance of less than 10 mL/min) or dialysis patients. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended.
- Patients with hepatic impairment: For patients with mild and moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. Severe liver failure, biliary cirrhosis, biliary obstruction, bile secretion arrest
Do not administer this medicine to these patients.
- Elderly people over 65 years of age: Caution should be exercised when increasing the dose.
- Children: Administration of this drug is not recommended for pediatric patients under the age of 18 as the safety and efficacy have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, they can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant and lactating women)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe renal impairment (creatinine clearance less than 10 mL/min) (no experience with use)
4) Patients with severe liver impairment, biliary cirrhosis, biliary obstruction, or bile secretion arrest
5) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
6) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
7) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
8) Patients with severe aortic stenosis
9) Shock patients
3. Administer with caution to the following patients:
1) Patients with sodium and/or fluid deficiency
In placebo-controlled clinical trials, excessive hypotension was observed in 0.4% of patients with uncomplicated hypertension receiving this drug. In patients with an activated renin-angiotensin system who are taking angiotensin receptor antagonists (ARB antagonists) (e.g., volume and/or sodium depleted patients taking high doses of diuretics), symptomatic hypotension may occur. It is recommended that these conditions be corrected prior to administration of this drug or that close medical observation be observed upon initiation of treatment.
If low blood pressure occurs when taking this medicine, have the patient lie down and, if necessary, inject saline solution intravenously. Treatment can be continued after blood pressure stabilizes.
2) Patients with hyperkalemia
Caution should be exercised when coadministering this drug with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
3) Patients with renal artery stenosis
This drug may increase blood urea and serum creatinine in patients with bilateral or unilateral renal artery stenosis caused by valsartan or in patients with short stature and stenosis, so monitoring is recommended for safety.
4) Kidney transplant patient
There are no data to demonstrate the safe use of this drug in patients who have recently undergone a kidney transplant.
5) Angioedema
Angioedema (including swelling of the larynx and glottis) causing airway obstruction and/or swelling of the face, lips, and tongue has been reported in patients receiving valsartan. Some of these patients had experienced angioedema caused by other medications, such as ACE inhibitors. If angioedema occurs during administration of this drug, administration should be discontinued immediately and should not be re-administered.
6) Patients after heart failure or myocardial infarction
In general, caution is advised when using calcium channel antagonists such as amlodipine in patients with severe congestive heart failure (NYHA class III or IV). In a placebo-controlled trial (PRIASE-2) in patients with NYHA stage III or IV heart failure of nonischemic origin, amlodipine was reported to be associated with an increase in pulmonary edema despite clearly reducing exacerbations of heart failure compared to placebo.
In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., severe heart failure), administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
7) Patients with acute myocardial infarction
In patients who started taking or increased the dose of calcium channel blockers (e.g., amlodipine) (especially patients with severe obstructive coronary artery disease), increases in the frequency, duration, or severity of angina or acute myocardial infarction were rarely reported.
8) Patients with aortic and mitral valve stenosis and obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is required when administering amlodipine to patients with aortic or mitral atresia or obstructive hypertrophic cardiomyopathy.
9) Dual blockade of renin-angiotensin-aldosterone system (RAAS):
Concomitant use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, including valsartan, is not recommended.
10) Patients with mild to moderate hepatic impairment (In patients with mild to moderate hepatic impairment, it is recommended that the daily dose of valsartan among the ingredients of this drug do not exceed 80 mg.)
4. Adverse reactions
1) The safety of this drug was evaluated in 5 controlled clinical trials in which 5,175 patients participated, of which 2,613 received amlodipine and valsartan in combination.
Adverse reactions were classified according to frequency of occurrence into very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1,000, <1/100), rare (≥ 1/10,000, <1/1,000), and very rare (<1/10,000), including independent reports. In the same frequency group, adverse reactions were organized in decreasing order of seriousness.
<Table 1> Adverse reactions that occurred (please refer to the attached document for details)
2) Additional information on combination use
In a double-blind, drug- or placebo-controlled clinical trial, the incidence of peripheral edema was found to be statistically lower in the combined amlodipine group (5.8%) compared to the amlodipine group administered alone (9%).
3) Additional information about each active ingredient
Although not observed in clinical trials and post-marketing experience with this drug, adverse reactions previously reported for each ingredient may occur.
① Valsartan
<Table 2> Adverse drug reactions that occurred when valsartan was administered alone
(Please refer to the attached document for further details)
Regardless of the causal relationship with the drug, the following symptoms were reported during clinical trials: insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
② Amlodipine
Regardless of the causal relationship with the drug, adverse reactions reported in amlodipine clinical trials are listed in <Table 3>.
<Table 3> Adverse reactions that occurred when amlodipine was administered alone
(Please refer to the attached document for further details)
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization. Leukopenia, thrombocytopenia, confusion, exfoliative dermatitis, Stevenson-Johnson syndrome, photosensitivity reaction, and toxic epidermal necrolysis have been reported (frequency unknown).
4) Domestic post-marketing survey results
(1) As a result of a use result survey conducted on 859 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 5.12% (44 people, 56 cases) regardless of causal relationship.
The incidence of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 1.75% (15 people, 19 cases), headache 0.47% (4 people, 4 cases), dizziness 0.35% (3 people, 3 cases), itching 0.35% (3 people, 3 cases), peripheral edema 0.23% (2 people, 2 cases), and hypotension. 0.23% (2 people, 2 cases), 1 case each of edema, chest pain, pain, cough, and enuresis.
Regardless of the causal relationship with this drug, no serious adverse events have been reported. A total of 9 cases were reported as unexpected adverse events, including 0.23% chest discomfort (2 people, 2 cases), pain, abdominal discomfort, reflux esophagitis, neck pain, hypercholesterolemia, hypoglycemia, and enuresis. A total of 2 unexpected drug adverse reactions occurred, 1 case of pain and 1 case of enuresis.
(2) As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, the following are newly identified adverse events that were statistically significantly more reported in this drug compared to the adverse events reported in all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
∙ Systemic abnormalities: chest pain, weight gain
∙ Musculoskeletal system: joint pain, skeletal pain, rhabdomyolysis
∙ Oral: Gum hyperplasia
∙ Gastrointestinal system: Gastritis
∙ Mental disorder: nervousness
∙ Nervous system: decreased sensation
∙ Skin and subcutaneous tissue abnormalities: Stevens-Johnson syndrome
5. General precautions
1) Be careful when driving and operating machines
Clinical trials have not been conducted on the effects on driving and using machinery. It should be taken into account that dizziness and fatigue may occur intermittently when driving or using machinery. As with other antihypertensive drugs, take special care when driving or operating machinery.
2) Valsartan
(1) Administration of this drug may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration. In such cases, stop administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
➀ Patients undergoing hemodialysis
② Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
③ Patients undergoing strict salt restriction
(2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of taking this drug. This depletion of sodium and body fluids before administration of this drug should be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
(3) Patients with renal artery stenosis: Short-term administration of this drug to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow and a decrease in glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
(4) It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment does not exceed 80 mg. This drug is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when this drug is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
(5) Patients receiving this drug after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of hypotension. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with this drug. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of this drug and/or diuretic should be considered.
(6) In patients with hyperkalemia, administration should be avoided except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
(7) There is no experience of use in patients who recently underwent kidney transplantation.
(8) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
3) Amlodipine
(1) Administration to heart failure patients: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in NYHA class III and IV heart failure patients without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared to placebo.
(2) Administration to patients with liver dysfunction: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
(3) Since the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration, so when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
(4) Since the effect appears slowly, it cannot be expected to be effective in unstable angina pectoris that requires emergency treatment.
6. Interaction
1) Valsartan
① Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
② Potassium: Caution should be exercised when using potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
③ Non-steroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect may be reduced when angiotensin II receptor antagonists are administered simultaneously with NSAIDs (e.g., aspirin as anti-inflammatory therapy, COX-2 inhibitors). In particular, the risk of kidney function deterioration may increase in elderly patients, patients with insufficient body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
④ Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
⑤ When valsartan was administered alone, no clinically significant drug interactions were observed with the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glibenclamide.
2) Amlodipine
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. The maximum daily dose of simvastatin in patients receiving amlodipine is 20 mg.
② CYP3A4 inhibitor: When the elderly administered a combination of 5 mg of amlodipine and 180 mg of diltiazem per day, the systemic exposure of amlodipine increased by 57%. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase the blood concentration of amlodipine more than diltiazem, so amlodipine should be administered with caution when co-administered with CYP3A4 inhibitors.
③ CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
④ Others: When amlodipine is administered alone, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin converting enzyme inhibitors, long-acting nitrate preparations, nitroglycerin sublingual tablets, digoxin, warfarin, atorovastatin, sildenafil, aluminum/magnesium (antacid), cimetidine, non-steroidal drugs. It was safe when used in combination with anti-inflammatory drugs, antibiotics, oral hypoglycemic agents, ethanol (alcohol), and cyclosporine.
⑤ Grapefruit juice: A single oral administration of 240 mL of grapefruit juice and 10 mg of amlodipine to 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodine.
⑥ Tacrolimus: When administered in combination with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II antagonists, a risk to the fetus cannot be excluded. Damage to the developing fetus and death have been reported in pregnant women taking angiotensin-converting enzyme inhibitors (a special group of drugs that act on the renin-angiotensin-allosterone system (RAAS)) during the second and third trimesters. And the use of ACE inhibitors in the first trimester is associated with a potential risk of fetal malformations. Spontaneous abortion, oligohydramnios, and renal dysfunction in newborns have been reported in pregnant women who accidentally took valsartan. Like other medications that act directly on the RAAS, this medication should not be used during pregnancy or if you plan to become pregnant. When prescribing drugs that act on RAAS to women who may become pregnant, doctors should explain the potential risks of these drugs during pregnancy. If pregnancy is confirmed during treatment with this drug, this drug should be discontinued as soon as possible.
2) It is not known whether valsartan and/or amlodipine are secreted into milk in humans, but in rats, valsartan was secreted into milk. Therefore, it is not recommended for breastfeeding women to use this medicine.
3) There have been no clinical studies on reproductive function of this drug or each single agent. There is no non-clinical data on reproductive function for this drug, but non-clinical tests conducted with each component of valsartan and amlodipine did not show an effect on reproductive function.
8. Administration to children
This drug is not recommended for use in patients under the age of 18 as there is insufficient data on its safety and effectiveness.
9. Administration to elderly people
Both components of this drug were well tolerated when similar doses were used in adults and the elderly, so normal doses are recommended.
10. Effect on clinical test values
1) Among patients with hypertension who received valsartan/amlodipine, there were very few patients whose test values clearly changed from baseline. The amlodipine/valsartan combination group (5.5%) and the valsartan alone group (5.5%) showed higher blood urea nitrogen (BUN) than the placebo group (4.5%).
2) An increase in liver function test values has occasionally been reported when administering valsartan, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
11. Treatment in case of overdose
I have no experience of overdosing on this drug. When overdosing on valsartan, the main symptoms may be low blood pressure accompanied by dizziness. Overdosage of amlodipine may cause reflex tachycardia by excessively dilating peripheral blood vessels. There have been reported cases of prolonged systemic hypotension leading to shock and even death.
If clinically significant hypotension occurs due to overdosage of this drug, active cardiovascular therapy should be implemented, including frequent monitoring of cardiac and respiratory function, keeping extremities elevated, and careful monitoring of circulating fluid volume and urine output. If the use of vasoconstrictors is not contraindicated, they may help restore vascular tone and blood pressure. Intravenous calcium gluconate may help reverse calcium channel blockage. Neither valsartan nor amlodipine are removed by hemodialysis. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors. Immediately after an overdose of this drug, inducing vomiting or gastric lavage may be considered. When medicinal charcoal was administered immediately to 2 hours after taking amlodipine in healthy volunteers, it significantly reduced amlodipine absorption.
12. Pharmaceutical equivalence test information
A. The test drug Valdipine Tablet 10/160 mg [KyungDong Pharm Co., Ltd.] and the reference drug Expo-designated 10/160 mg) [Novartis Korea Co., Ltd.] were orally administered as a single dose to healthy adults in a 2 In this case, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
(Please refer to the attached document for further details)
13. Others
In the embryo-fetal toxicity study in rats and in the 13-week animal study in rats and marmosets, there were no toxicological findings that would be considered significant in humans.
As a result of oral administration in rats for 13 weeks, glandular inflammation was observed in male rats administered more than 3/48 mg/kg/day of amlodipine/valsartan, but not in female rats. In marmosets, this result was not observed at any dose, but colitis was observed at high doses (no effects were observed below 5/80 mg/kg/day). In clinical trials, the frequency of gastrointestinal adverse reactions observed when administering this drug was similar to the frequency of adverse reactions observed when administered alone.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets (7 tablets/Alu-AluX4), 30 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 5items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 5 | Valdipine Tab. 5/80mg | Precautions for use | 2026.02.12 | PDF0117_201308565_Precautions for use_Valdipine tablets 5/80mg.pdf |
| 4 | Valdipine Tab. 5/80mg | Precautions for use | 2026.02.12 | PDF0348_201308565_Precautions for use_Valdipine tablets 5/80mg.pdf |
| 3 | Valdipine Tab. 5/80mg | Precautions for use | 2024.08.30 | PDFValdipine Tablet 5│80mg_Precautions for Use.pdf |
| 2 | Valdipine Tab. 5/80mg | Precautions for use | 2018.09.14 | PDF0262_201308565_Precautions for use (Valdipine tablets 5_80mg).pdf |
| 1 | Valdipine Tab. 5/80mg | Valdipine tablet 5/80 mg (precautions for use) | 2014.02.21 | HWP)Precautions for use and change preparation table (valsartan, amlodipine) |